Serological evidence for reactivation of EBV infection due to uraemic immunodeficiency

Nephrology Dialysis Transplantation

Volumn 12, Issue 10, 1997, Pages 2099-2104

  Winkelspecht, Bernd ^a,b   Mueller Lantzsch, Nikolaus ^a   Köhler, Hans ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

EBV infection; EBV reactivation; Immunodeficiency; Serology; Transplantation; Uraemia

Indexed keywords

VIRUS ANTIBODY;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY FAILURE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FEMALE; HEMODIALYSIS; HUMAN; IMMUNE DEFICIENCY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROLOGY; UREMIA; VIRUS REACTIVATION;

ADULT; ANTIBODIES, VIRAL; ANTIGENS, NUCLEAR; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNE TOLERANCE; IMMUNOGLOBULIN G; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NUCLEAR PROTEINS; RECOMBINANT PROTEINS; REFERENCE VALUES; UREMIA; VIRUS ACTIVATION;

EID: 0030815061     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/12.10.2099     Document Type: Article

References (21)

1. Purtilo DT. Malignant lymphoproliferative diseases induced by EBV in immunodeficient patients, including X-linked cytogenetic, and familial syndromes. Cancer Genetics and Cytogenetics 1981; 4: 251-268
2. Hanto D, Frizzera G, Gajl-Peczalska K, Simmons R. EBV, immunodeficiency, and B cell lymphoproliferation. Transplantation 1985; 39: 461-470
3. Straus SE, Cohen JE, Tosato G. Meier J. Epstein-Barr virus infections: biology, pathogenesis, and management. Ann Intern Med 1993; 118: 45-58
4. Jones C, Bleau B, Buskard N et al. Simultaneous development of diffuse immunoblastic lymphoma in recipients of renal transplants from a single cadaver donor: transmission of EBV and triggering by OKT3. Am J Kidney Dis 1994; 23: 130-134
5. Swinnen LJ, Costanzo-Nordin MR, Fisher SG et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 1990; 323: 1723-1728
6. Girndt M, Köhler H, Schiedhelm-Weick E, Meyer zum Büschenfelde JCH, Fleischer B. T cell activation in hemodialysis patients: Evidence for a role of the B7/CD28 pathway. Kidney Int 1993; 44: 359-365
7. Dumann H, Meuer SC, Meyer zum Büschenfelde KH, Köhler H. Hepatitis-B vaccination and interleukin 2 receptor expression in chronic renal failure. Kidney Int 1990; 38: 1164-1168
8. Meuer SC, Dumann H, Meyer zum Büschenfelde KH, Köhler H. Low dose interleukin 2 induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination. Lancet 1989; I: 15-18
9. Köhler H, Girndt M, Dumann H, Klingel R. The immune defect in kidney failure. I. Clinical manifestations. II. Mechanism of 'uremic' immune defect. Dtsch Med Wochenschr 1993; 118: 757-761; 790-795
10. Cockfield SM, Preiksaitis JK, Jewell LD, Parfrey NA. Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center. Transplantation 1993; 56: 88-96
11. Cohen JI. Epstein-Barr Virus lymphoproliferative disease associated with acquired immunodeficiency. Medicine 1991; 70: 137-160
12. Prang N, Wolf H, Schwarzmann F. Evidence for lytic activity of EBV in peripheral blood using PCR on BZLF1-RNA in chronic infection und graft rejections. Poster presentation, Gesellschaft für Virologie, Frankfurt/Main, March 1994
13. Yamamoto T, Nakajima Y, Yamamoto M et al. Epstein-Barr virus activity in patients on chronic hemodialysis. Nephron 1995; 70: 449-454
14. Lehtinen T, Lumio J, Dillner J et al. Increased risk of malignant lymphoma indicated by elevated EBV antibodies- a prospective study. Cancer Causes Control 1993; 4: 187-193
15. Lennette E, Rymo L, Yadav M et al. Disease related differences in antibody patterns against EBV-encoded nuclear antigens EBNA1, EBNA2 and EBNA6. Eur J Cancer 1993; 29A: 1584-1589
16. Winkelspecht B, Gräßler F, Pees HW, Mueller-Lantzsch N. Anti-EBNA1/anti-EBNA2 ratio decreases significantly in patients with progression of HIV infection. Arch Virol 1996; 141: 857-864
17. Youinou P, Buisson M, Berthelot J et al Anti-EBV-nuclear antigen-1, -2a and -2b antibodies in rheumatoid arthritis patients and their relatives. Autoimmunity 1992; 13: 225-231
18. Henle W, Henle G, Andersson J et al. Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection. Proc Natl Acad Sci USA 1987; 84: 570-574
19. Summers M, Smith G. A manual of methods for baculovirus vectors and insect culture procedures. Bulletin 1555: 1987: Texas Agriculture Experimental Station, College Station, TX
20. Hille A, Klein K, Bäumler S, Grässer FA, Mueller-Lantzsch N. Expression of Epstein-Barr virus nuclear antigen 1, 2a and 2b in the baculovirus expression system: serological evaluation of human antibodies to these proteins. J Med Virol 1993; 39: 233-241
21. Hornef MW, Bein G, Fricke L et al. Coincidence of Epstein-Barr virus reactivation, cytomegalovirus infection, and rejection episodes in renal transplant recipients. Transplantation 1995; 60: 474-480